ClinicalTrials.gg
RecruitingNCT06689891Updated Jan 16, 2026

Video-Based Pelvic Floor Muscle Therapy

An interventional study of Pelvic Floor Muscle Therapy Website in Pelvic Floor Disorder and Pelvic Floor Muscle Exercise, sponsored by Yale University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Yale University · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 61 studies in Pelvic Floor Disorders with a site in United States — 12 open to participants now, 16 under way, none of them phase 3. Pelvic Floor Disorders · United States.

Planned enrollment
36th of 50
20 · median 57
Started
2025
with 4 others
No phase
38 of 61
7 open now
Primary completion
2026-12
later than 5 of 15 live
Registered
52nd of 61
by date

Among the 61 studies in Pelvic Floor Disorders with a site in United States, this one is the 36th largest by planned enrollment of the 50 interventional ones that give a count, is one of 5 that started in 2025, is one of 38 with no phase, reaches primary completion later than 5 of the 15 other live ones, and was the 52nd registered.

Pelvic Floor Disorders

212 studies on the registry are indexed under Pelvic Floor Disorders; 46 are open to participants now.

Browse Pelvic Floor Disorders studies →

Open to participants now

12 of the 61 studies in Pelvic Floor Disorders with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 27 Pelvic Floor Disorders studies recruiting now, 17 (63%) set no upper age limit and 10 (37%) stop at 75 or younger; none take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Pelvic Floor Disorders with a site in United States, or all of them as a file.
02

Study summary

This study is a feasibility, pilot trial of remote, video-based pelvic floor muscle therapy (PFMT) for patients with pelvic floor disorders, including pelvic organ prolapse, urinary incontinence and anorectal dysfunction. PFMT has been shown to improve these symptoms in multiple studies.

Read the detailed description

This will be a feasibility and acceptability trial of a novel remote, web-accessible PFMT curriculum, designed by pelvic floor physical therapists.

Patients will be expected to complete a 5-10-minute survey at initial enrollment. They will have one in-person session with a pelvic floor therapist prior to starting the 8-week video-based PFMT course. Afterwards, they will have a final in person session with a pelvic floor therapist along with a final set of surveys that should take an estimated 10-15 minutes.

The primary objective is to the determine the feasibility and accessibility of using a video-based PFMT for patients with pelvic floor dysfunction.

The secondary objective is to determine whether video-based PFMT can improve symptomatology and quality of life.

03

Conditions studied

  • Pelvic Floor Disorder
  • Pelvic Floor Muscle Exercise
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of pelvic floor dysfunction with referral for PFR
  • English-speaking

Exclusion criteria

Exclusion Criteria:

  • Unable to access web-based videos
  • Unable to speak English
05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Video-based pelvic floor muscle therapy (PFMT)

    Patients will complete a series of surveys before and after the intervention. They will complete 8 weeks of video-based PFMT with an initial and final in-person session with a pelvic floor therapist.

    Device: Pelvic Floor Muscle Therapy Website

Interventions

  • DevicePelvic Floor Muscle Therapy Website

    8-week video-based, self-directed PFMT course

06

What researchers measure

Primary outcomes

  1. System Usability Scale (SUS) Score

    The SUS is a 10-question survey that measures how easy a product or system is to use. Total score range from 0-100 with higher scores indicating better usability.

    Time frame: 8 weeks

  2. Percentage of participants video completion

    Percentage of participants that complete at least 80% of the videos

    Time frame: 8 weeks

  3. Change in graded evaluation of exercises by pelvic floor therapist

    Participants will be assessed and graded and by the pelvic floor physical therapist as below: 1 - cannot perform exercise, 2 - can partially perform exercise (needs some cueing and assistance), 3 - can independently perform exercise

    Time frame: baseline and 8 weeks

  4. Adverse Events

    Number of participants that experience at least one adverse event.

    Time frame: up to 8 weeks

Secondary outcomes

  1. Short Form-12 (SF-12)

    The SF-12 is an abbreviated version of the SF-36. The SF-12 is a validated survey that assesses a patient's health related quality of life across eight domains. The total score range is 0-100 with a physical component summary and a mental component summary. A higher score indicates better health for each of those components.

    Time frame: baseline and week 9

  2. Cleveland Clinic Incontinence Score (CCIS)

    The CCIS is a health-related quality of life measure that assesses how often and to what degree incontinence affects a person's life. The total score ranges from 0 to 20, with higher scores indicating higher levels of incontinence.

    Time frame: baseline and week 9

  3. Patient Assessment of Constipation Symptoms (PAC-SYM)

    The PAC-SYM is a questionnaire used to assess the severity of constipation symptoms in adults. Total score range 0-4 with higher scores indicating more severe constipation.

    Time frame: baseline and week 9

  4. International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)

    The ICIQ-SF is a brief patient-completed questionnaire that measures the impact of urinary incontinence (UI) on quality of life (QoL). The ICIQ-UI SF is scored on a scale of 0-21. A score of zero means no urine leakage and no impact on QoL.

    Time frame: baseline and week 9

  5. Pelvic Organ Prolapse Symptom Score (POP-SS)

    The POP-SS is a questionnaire that measures the severity of pelvic organ prolapse symptoms. The total score ranges from 0-28, with higher scores indicating more severe symptoms.

    Time frame: baseline and week 9

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2026, 18 months after the start.

Of 100 non-industry interventional studies with no phase under Pelvic Floor Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 31. This study's planned 18 months is close to that.

Counting every sponsor, half of 106 studies reached it within 17 months; a quarter within 7 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2024
First posted
Nov 15, 2024
StartActual
Jun 9, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06689891
Lead sponsor
Yale University
Responsible party
Sponsor
First posted
Nov 15, 2024
Start date
Jun 9, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jan 16, 2026

Study contacts

Anne Mongiu, MD, PhD
Contact
Anne.mongiu@yale.edu
203-785-2616
Samantha Linhares, MD
Contact
Samantha.linhares@yale.edu
203-843-6140

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion